Replimune Group, Inc.
Tremor tracks 6 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 4 insiders sold shares within a monthSince Aug 17, 2026+3.9
Trials
- REPLReplimune, Inc.14Calm
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Running, no new patientsPhase 2231 patientsMain results: Sep 2025 - REPLReplimune, Inc.4Calm
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Signing up patientsPhase 3400 patientsMain results: Sep 30, 2030 - REPLReplimune, Inc.4Calm
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Running, no new patientsPhase 1/269 patientsMain results: Jul 2029 - REPLReplimune, Inc.4Calm
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Signing up patientsPhase 260 patientsMain results: Dec 1, 2027 - REPLReplimune, Inc.4Calm
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Signing up patientsPhase 2/3280 patientsMain results: Jan 2030 - REPLReplimune, Inc.4Calm
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Running, no new patientsPhase 2340 patientsMain results: Jun 2028
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
13 sales (12 not pre-planned) · 0 purchases
- Dhingra KapilBoard member · Nov 2, 2026Sold 21,500 sharesabout $409 thousand · not pre-planned
- Hill Emily LuisaChief Financial Officer · Aug 17, 2026Sold 9,256 sharesabout $132 thousand · not pre-planned
- Patel SushilChief Executive Officer · Aug 10, 2026Sold 39,341 sharesabout $510 thousand · not pre-planned
- Hill Emily LuisaChief Financial Officer · Aug 10, 2026Sold 11,448 sharesabout $148 thousand · not pre-planned
- Xynos KonstantinosChief Medical Officer · Aug 10, 2026Sold 11,447 sharesabout $148 thousand · not pre-planned
- Schwendenman AndrewChief Accounting Officer · Aug 10, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.